JUBLPHARMABSEJubilant Pharmova LtdHighNegative
Announced Fri, 22 May · 19:42 IST

Tax Demand order received by company''s step down subsidiary

Regulatory & Legal View source PDF

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.8%1-day move
₹998.00
prior close
₹1006.45
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.9-4.4-4.4-4.7-0.8-0.8-0.5-2.2-2.6-3.1-2.1-3.4-2.4
Up moveDown movePending
AI summary

Jubilant Pharmova's wholly owned step-down subsidiary Jubilant Generics Limited received a tax order from the Income Tax Department dated May 21, 2026. The order makes tax adjustments of Rs. 107.89 crores, primarily arising from transfer pricing adjustments for FY 23. The company believes the adjustments ignore its factual contentions and plans to file an appeal before the Commissioner of Income Tax (Appeals). An application before the Advance Pricing Authority has also been filed. The company expects the tax adjustments to be deleted following adjudication. While Deferred Tax Assets will be reduced by Rs. 37.70 crores, the company does not anticipate any material financial implications as it expects to get relief from appellate authorities.

Likely market impact

The tax adjustment is being contested and the company expects relief, so no immediate material financial impact is anticipated. However, the Rs. 37.70 crore reduction in Deferred Tax Assets may have some near-term accounting impact. The stock could see minor pressure until the appeal is resolved.